We also examined whether the increase in GPx3 following supplementation was associated with the improvement in the eGFR and found that the increase in GPx3 from inclusion to 48 months was associated with a corresponding increase in CKD-EPI Cys C (r = 0.17, p = 0.033). This evidence concerns the gene GPX3 and chronic kidney disease.